Literature DB >> 19011597

Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats.

A M Sonabend1, I V Ulasov, Y Han, C E Rolle, S Nandi, D Cao, M A Tyler, M S Lesniak.   

Abstract

Conditionally replicative adenoviruses (CRAds) are often evaluated in mice; however, normal and cancerous mouse tissues are poorly permissive for human CRAds. As the cotton rat (CR) is a semipermissive animal and the Syrian hamster (SH) is a fully permissive model for adenoviral replication, we compared them in a single study following intracranial (i.c.) injection of a novel glioma-targeting CRAd. Viral genomic copies were quantified by real-time PCR in brain, blood, liver and lung. The studies were corroborated by immunohistochemical, serological and immunological assays. CR had a multiple log higher susceptibility for adenoviral infection than SH. A similar amount of genomic copies of CRAd-Survivin-pk7 and human adenovirus serotype 5 (AdWT) was found in the brain of CR and in all organs from SH. In blood and lung of CR, AdWT had more genomic copies than CRAd-Survivin-pk7 in some of the time points studied. Viral antigens were confirmed in brain slices, an elevation of serum transaminases was observed in both models, and an increase in anti-adenoviral antibodies was detected in SH sera. In conclusion, CR represents a sensitive model for studying biodistribution of CRAds after i.c. delivery, allowing for the detection of differences in the replication of CRAd-Survivin-pk7 and AdWT that were not evident in SH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011597      PMCID: PMC2657193          DOI: 10.1038/cgt.2008.80

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  35 in total

Review 1.  Oncolytic adenoviruses as antiglioma agents.

Authors:  Hong Jiang; Frank McCormick; Frederick F Lang; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  Expert Rev Anticancer Ther       Date:  2006-05       Impact factor: 4.512

2.  China approves world's first oncolytic virus therapy for cancer treatment.

Authors:  Ken Garber
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

3.  Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma.

Authors:  Wesley Hsu; Maciej S Lesniak; Betty Tyler; Henry Brem
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

Authors:  Eric J Small; Michael A Carducci; James M Burke; Ron Rodriguez; Lawrence Fong; Lynn van Ummersen; D C Yu; Junko Aimi; Dale Ando; Peter Working; David Kirn; George Wilding
Journal:  Mol Ther       Date:  2006-05-09       Impact factor: 11.454

5.  Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.

Authors:  Maria A Thomas; Jacqueline F Spencer; Marie C La Regina; Debanjan Dhar; Ann E Tollefson; Karoly Toth; William S M Wold
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

6.  [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].

Authors:  Zhong-Jun Xia; Jian-Hua Chang; Li Zhang; Wen-Qi Jiang; Zhong-Zhen Guan; Ji-Wei Liu; Yang Zhang; Xiao-Hua Hu; Guo-Hua Wu; Hua-Qing Wang; Zheng-Chang Chen; Jian-Chao Chen; Qing-Hua Zhou; Jian-Wei Lu; Qing-Xia Fan; Jian-Jin Huang; Xiao Zheng
Journal:  Ai Zheng       Date:  2004-12

Review 7.  Oncolytic adenoviral therapy for glioblastoma multiforme.

Authors:  Adam M Sonabend; Ilya V Ulasov; Yu Han; Maciej S Lesniak
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

8.  Local delivery of doxorubicin for the treatment of malignant brain tumors in rats.

Authors:  Maciej S Lesniak; Urvashi Upadhyay; Rory Goodwin; Betty Tyler; Henry Brem
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

9.  Cotton rat tumor model for the evaluation of oncolytic adenoviruses.

Authors:  Karoly Toth; Jacqueline F Spencer; Ann E Tollefson; Mohan Kuppuswamy; Konstantin Doronin; Drew L Lichtenstein; Marie C La Regina; Gregory A Prince; William S M Wold
Journal:  Hum Gene Ther       Date:  2005-01       Impact factor: 5.695

10.  The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.

Authors:  Winan J Van Houdt; Yosef S Haviv; Baogen Lu; Minghui Wang; Angel A Rivera; Ilya V Ulasov; Martine L M Lamfers; Daniel Rein; Maciej S Lesniak; Gene P Siegal; Clemens M F Dirven; David T Curiel; Zeng B Zhu
Journal:  J Neurosurg       Date:  2006-04       Impact factor: 5.115

View more
  21 in total

Review 1.  Oncolytic viral therapy of malignant glioma.

Authors:  Jacqueline Nuss Parker; David F Bauer; James J Cody; James M Markert
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

2.  A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.

Authors:  Mariana Puntel; A K M G Muhammad; Marianela Candolfi; Alireza Salem; Kader Yagiz; Catherine Farrokhi; Kurt M Kroeger; Weidong Xiong; James F Curtin; Chunyan Liu; Niyati S Bondale; Jonathan Lerner; Robert N Pechnick; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

Review 3.  Oncolytic viruses: overcoming translational challenges.

Authors:  Jordi Martinez-Quintanilla; Ivan Seah; Melissa Chua; Khalid Shah
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

4.  Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Authors:  Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; John E Sagartz; William S M Wold; Karoly Toth
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

5.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Authors:  Anniina Koski; Lotta Kangasniemi; Sophie Escutenaire; Sari Pesonen; Vincenzo Cerullo; Iulia Diaconu; Petri Nokisalmi; Mari Raki; Maria Rajecki; Kilian Guse; Tuuli Ranki; Minna Oksanen; Sirkka-Liisa Holm; Elina Haavisto; Aila Karioja-Kallio; Leena Laasonen; Kaarina Partanen; Matteo Ugolini; Andreas Helminen; Eerika Karli; Päivi Hannuksela; Saila Pesonen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

6.  The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.

Authors:  Alex L Tobias; Bart Thaci; Brenda Auffinger; Esther Rincón; Irina V Balyasnikova; Chung Kwon Kim; Yu Han; Lingjiao Zhang; Karen S Aboody; Atique U Ahmed; Maciej S Lesniak
Journal:  Stem Cells Transl Med       Date:  2013-08-07       Impact factor: 6.940

7.  Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.

Authors:  A K M G Muhammad; M Puntel; M Candolfi; A Salem; K Yagiz; C Farrokhi; K M Kroeger; W Xiong; J F Curtin; C Liu; K Lawrence; N S Bondale; J Lerner; G J Baker; D Foulad; R N Pechnick; D Palmer; P Ng; P R Lowenstein; M G Castro
Journal:  Clin Pharmacol Ther       Date:  2010-02-17       Impact factor: 6.875

8.  The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  B A Young; J F Spencer; B Ying; K Toth; W S M Wold
Journal:  Cancer Gene Ther       Date:  2013-08-09       Impact factor: 5.987

9.  Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells.

Authors:  Sadhak Sengupta; Ilya V Ulasov; Bart Thaci; Atique U Ahmed; Maciej S Lesniak
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

10.  Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.

Authors:  Brenda Auffinger; Atique U Ahmed; Maciej S Lesniak
Journal:  Front Oncol       Date:  2013-02-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.